HC Wainwright Reaffirms “Buy” Rating for Sana Biotechnology (NASDAQ:SANA)

Sana Biotechnology (NASDAQ:SANA)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 181.69% from the company’s previous close.

Other equities analysts have also issued reports about the company. JMP Securities lowered Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. Citigroup increased their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a report on Friday, August 9th.

Sana Biotechnology Trading Down 1.7 %

Shares of SANA opened at $2.84 on Monday. The company has a market capitalization of $631.80 million, a price-to-earnings ratio of -1.98 and a beta of 1.44. The stock has a 50 day moving average of $4.14 and a 200 day moving average of $5.73. Sana Biotechnology has a 12 month low of $2.74 and a 12 month high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. As a group, equities research analysts predict that Sana Biotechnology will post -1.13 earnings per share for the current year.

Insider Transactions at Sana Biotechnology

In other news, Director Richard Mulligan sold 150,000 shares of the firm’s stock in a transaction on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the completion of the transaction, the director now directly owns 2,848,121 shares of the company’s stock, valued at $11,620,333.68. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 31.10% of the company’s stock.

Institutional Investors Weigh In On Sana Biotechnology

Several large investors have recently added to or reduced their stakes in SANA. Blue Trust Inc. boosted its stake in Sana Biotechnology by 1,246.6% during the third quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after buying an additional 12,154 shares during the period. Cornercap Investment Counsel Inc. bought a new stake in Sana Biotechnology during the third quarter valued at $67,000. Algert Global LLC bought a new stake in Sana Biotechnology during the second quarter valued at $73,000. XTX Topco Ltd bought a new stake in Sana Biotechnology during the second quarter valued at $100,000. Finally, Dark Forest Capital Management LP boosted its stake in Sana Biotechnology by 112.0% during the second quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company’s stock valued at $149,000 after buying an additional 14,430 shares during the period. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.